IL-22 Dimer Therapy Cycles for Gut-Focused GvHD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies to treat graft versus host disease (GvHD) often impair immune function and limit graft versus leukemia/lymphoma responses, particularly affecting intestinal tissues and contributing to high mortality rates.
Innovation Solution
Administering an IL-22 dimer comprising two monomeric subunits with an IL-22 domain and an Fc domain, along with immunosuppressive therapy, in multiple cycles separated by rest periods, tailored to individual gut microbiota profiles and Ann Arbor scores.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If current immunosuppressive strategies are used to treat GvHD, then GvHD symptoms are reduced, but post-transplant immune function and therapeutic graft versus leukemia/lymphoma responses are limited
Solution Approach 1:
The patent applies local quality by selectively modulating immune responses in specific tissues (intestinal epithelium) rather than systemically suppressing all immune functions. IL-22 treatment specifically targets gut mucosal healing while preserving systemic immune responses needed for anti-leukemia activity and infection defense.
Solution Approach 2:
The patent uses IL-22 as an intermediary molecule that mediates between the harmful graft-versus-host immune response and the need for host tissue recovery. IL-22 acts as a selective immunomodulator that promotes epithelial regeneration without broadly suppressing immune function, thereby resolving the contradiction between treating GvHD and maintaining immune reliability.
2Object-affected harmful factors
If aggressive immunosuppressive therapy is administered to treat acute GvHD, then intestinal cell pathology is reduced, but therapeutic graft versus leukemia/lymphoma responses are compromised
Solution Approach 1:
The patent applies local quality by selectively modulating immune responses in specific tissues (intestinal epithelium) rather than systemically suppressing all immune functions. IL-22 treatment specifically targets gut mucosal healing while preserving systemic immune responses needed for anti-leukemia activity and infection defense.
Solution Approach 2:
The patent uses IL-22 as an intermediary molecule that mediates between the harmful graft-versus-host immune response and the need for host tissue recovery. IL-22 acts as a selective immunomodulator that promotes epithelial regeneration without broadly suppressing immune function, thereby resolving the contradiction between treating GvHD and maintaining immune reliability.
3Reliability
If IL-22 dimer is administered in continuous high doses, then gut microbiota diversity and GvHD response improve, but treatment complexity and duration increase
Solution Approach 1:
The patent applies periodic action by administering IL-22 dimer in cyclic regimens with scheduled intervals rather than continuous administration. This periodic dosing strategy maintains therapeutic efficacy while allowing immune system recovery periods, thereby reducing treatment complexity and improving patient compliance without compromising GvHD response rates.
Data Source
AI summary
The present application provides methods for treating graft versus host disease (GvHD) by administering a composition an agent comprising an IL-22 (such as an IL-22 dimer), and optionally an immunosuppressive therapy. The treatment can be administered for multiple cycles which are separated by a rest period and/or individuals who have a specific Ann Arbor score or a characterized gut microbiota profile. The present application also provides methods of identifying or selecting individuals suitable for such treatments.